Omnicell enters its third-quarter report with an odd split personality. Management has raised its full-year profit outlook three times this year, yet last quarter it also cut the low end of its 2026 product bookings forecast by $85 million, leaving a $135 million range with only five months to go. When a company sounds more confident about margins than about when customers will sign, the next set of numbers tends to be judged on the second issue, not the first.
The headline figures should look softer than last quarter by design. Consensus calls for non-GAAP earnings of $0.42 a share on revenue of $303.5 million, a 2.3% decline from a year ago. That revenue estimate sits just below the midpoint of management's $301 million to $307 million range, while the EPS estimate lands near the top of the $0.35 to $0.43 guide. The Earnings Whisper of $0.51 is more aggressive, sitting above the high end of guidance and well above the $0.32 earned a year ago. That suggests the people tracking this name expect Omnicell's cost discipline to produce another comfortable beat, which raises the bar for what counts as a good print. The sequential drop is largely mechanical: the second quarter was flattered by a one-time $15 million tariff refund, and the guided EBITDA of $32 million to $37 million reflects that windfall rolling off.
The more consequential number will not appear in the EPS line. Management attributed the bookings cut to deal timing rather than weakening demand, arguing that competitive conversions and large enterprise evaluations now take quarters or even years as both Omnicell and its largest rival refresh their platforms at the same time. Evidence that supports that story would include progress converting a pipeline management called meaningfully larger than in recent years, more wins like the competitive Titan XT conversion at a Southeast health system, and confirmation that Titan XT remains on track to ship in the back half of 2026. A narrowing of the bookings range toward the upper half would be a strong signal. Holding the range unchanged, or pulling down the $560 million top, would suggest the timing explanation is starting to look like a demand problem.
Two cost and revenue-quality questions also deserve attention. Memory chip prices have reportedly risen about fivefold, adding roughly $6 million of cost in the second half and an estimated 80 basis points of product gross margin pressure. Gross margin had climbed to 50% last quarter with tariff help, from 44% for all of 2025, so investors will want to see how much of that improvement survives without the refund. Separately, the year-end recurring revenue target was trimmed to $660 million to $680 million because consumables are ramping more slowly than expected; any further slippage would undercut the recurring revenue story that underpins the valuation.
The market has been unconvinced. Shares are up 2.7% since the last report, trailing the S&P 500 by nearly 2 percentage points, and at $36.49 the stock sits below its 200-day moving average of $39.57. It trades in the upper part of its post-earnings range of $31.98 to $38.00 but well beneath the prior quarter's band, which reached above $48. Sentiment remains mildly bearish, though slightly less so than heading into the last report, consistent with a stock that has stabilized without regaining trust.
Another EPS beat is likely priced in, given the whisper number. What will determine whether the narrative holds is whether management can show that the widened bookings range was a cautious hedge rather than an early warning. Tightening that range upward while reaffirming the raised profit outlook would let investors credit the margin gains as durable; widening the uncertainty again would leave Omnicell looking like a cost story waiting for a growth story to arrive.